Alzamend Neuro, Inc. filed a Form 8-K with the SEC on November 18, 2026, disclosing that the company presented at the annual meeting of the Society for Neuroscience on that same date.
Key Highlights
- Presentation date: Alzamend Neuro disclosed it presented at the Society for Neuroscience annual meeting on November 18, 2026.
- Disclosure type: The filing was made under Item 7.01, Regulation FD Disclosure.
- Exhibit furnished: A copy of the presentation was furnished as Exhibit 99.1 and incorporated by reference in the filing.
- Not deemed filed: According to the filing, the information under Item 7.01 and Exhibit 99.1 "shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended."
- Emerging growth company: The registrant indicated it qualifies as an emerging growth company under applicable SEC rules.
Alzamend Neuro's Neuroscience Conference Disclosure Under Regulation FD
Alzamend Neuro, Inc. (NASDAQ:ALZN), a Delaware-incorporated company headquartered at 3480 Peachtree Road NE, Suite 103, Atlanta, GA 30326, filed a current report on November 18, 2026, to disclose a presentation made at the annual meeting of the Society for Neuroscience. The filing was submitted under Item 7.01, which covers Regulation FD disclosures, and was signed by David J. Katzoff, Chief Financial Officer, on behalf of the registrant.
According to the filing, the presentation is attached as Exhibit 99.1 and is incorporated by reference into the report. The company disclosed that in accordance with General Instruction B.2 of Form 8-K, the information furnished under Item 7.01 and Exhibit 99.1 is not deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not automatically incorporated by reference into filings under the Securities Act of 1933, as amended, unless expressly referenced. The filing also noted that "this report will not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD."
The filing noted that the current report and its exhibits may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, and that such statements "involve risks, uncertainties and reflect the Registrant's judgment as of the date of this Current Report." The company cautioned that actual results could differ materially from those anticipated, and that investors should not rely unduly on such statements.
What Was Disclosed
Alzamend Neuro, Inc. reported via a Regulation FD current report that it presented at the Society for Neuroscience annual meeting on November 18, 2026, furnishing the presentation as Exhibit 99.1. The filing was signed by CFO David J. Katzoff.





Please wait processing your request...